BioSpace News Archive

Business

Medtronic CEO Talks Value-Based Care, Addresses Criticism of M&A Strategy at JPM

In his opening presentation at JPM, he highlighted one major product to show how the Irish medtech company is pursuing value-based care.

January 9, 2018
·
1 min read
Shire to Break Up Business Into Two Companies

Shire is splitting into two separate internal business units, Rare Disease Division and Neuroscience Division.

January 9, 2018
·
2 min read
·
Mark Terry
Business

Jobs Lost as Cellectar Biosciences Shutters Manufacturing Operations

Cellectar Biosciences is closing its manufacturing operations and contracting them out.

January 9, 2018
·
2 min read
·
Mark Terry
Business

Adaptimmune’s CMO Moves Forward With SPEAR T Cell Therapies

Adaptimmune is making strides on becoming a fully integrated cell therapy company behind its T Cell Receptor technology

January 9, 2018
·
3 min read
·
Alex Keown
Business

Ally Bridge and LifeTech Scientific Join to Invest in MedTech Companies

The two companies will invest as partners in global medtech enterprises with the goal of accelerating their market entry and commercialization in China.

January 9, 2018
·
1 min read
Business

ICON Issues Financial Guidance for Full Year 2018

For the full year 2018 revenue will be in the range of $1,870 - $1,930 million, representing growth of 7 - 10% and earnings per share will be in the range of $5.89 - $6.09, representing growth of 10 - 13%.

January 9, 2018
·
4 min read
Business

ICON Appoints Dr. James Cummings as President of ClinicalRM

Dr. Cummings has over 20 years’ experience within the global health and government research and development industries.

January 9, 2018
·
4 min read
Business

AbSci Appoints William F. Bennett, PhD to Scientific Advisory Board

A pioneer of the biotech industry, Dr. Bennett brings his decades of experience in downstream process development, protein purification, and regulatory affairs to the AbSci team.

January 9, 2018
·
2 min read
Drug Development

BerGenBio Meets First Efficacy Endpoint in Phase II Trial With Selective AXL Inhibitor BGB324 (bemcentinib) in NSCLC

The trial is enrolling patients with activating EGFR mutations across three settings.

January 9, 2018
·
8 min read
FDA

Xcision Wins FDA 510(k) OK for Breast Cancer GammaPod Stereotactic Radiotherapy System

With GammaPod, radiation oncologists will be at the forefront of a new era in cancer care by providing stereotactic radiotherapy treatments for the breast.

January 9, 2018
·
4 min read